logotype
  • Week's top
  • Latest news
  • Unread news
  • Subscribe

Science X Account

Click here to sign in with or

Forget Password?

Not a member? Sign up

Learn more

  • Addiction
  • Alzheimer's disease & dementia
  • Arthritis & Rheumatism
  • Attention deficit disorders
  • Autism spectrum disorders
  • Biomedical technology
  • Cardiology
  • Dentistry
  • Diabetes
  • Diseases, Conditions, Syndromes
  • Endocrinology & Metabolism
  • Gastroenterology
  • Genetics
  • Gerontology & Geriatrics
  • Health
  • Health informatics
  • HIV & AIDS
  • Immunology
  • Inflammatory disorders
  • Medical economics
  • Medical research
  • Medications
  • Neuroscience
  • Obstetrics & gynaecology
  • Oncology & Cancer
  • Ophthalmology
  • Other
  • Overweight & Obesity
  • Parkinson's & Movement disorders
  • Pediatrics
  • Psychology & Psychiatry
  • Radiology & Imaging
  • Sleep disorders
  • Sports medicine & Kinesiology
  • Surgery
  • Vaccination
  • Asthma
  • Breast cancer
  • Cardiovascular disease
  • Chronic obstructive pulmonary disease
  • Colon cancer
  • Coronary artery disease
  • Dementia
  • Depression
  • Heart attack
  • Heart disease
  • High blood pressure
  • Influenza
  • Kidney disease
  • Leukemia
  • Lung cancer
  • Malaria
  • Melanoma
  • Multiple sclerosis
  • Myocardial infarction
  • Ovarian cancer
  • Post traumatic stress disorder
  • Rheumatoid arthritis
  • Schizophrenia
  • Skin cancer
  • Stroke
  • Type 2 diabetes
  • Full List »
  1. Home
  2. Archive
  3. 06/07/2019

Archive: 06/07/2019

Data demonstrate efficacy of more flexible dose of regorafenib to relieve side-effects in mCRC patients

Medical oncologists administer anticancer drug regorafenib to try to improve overall survival in patients with metastatic colorectal cancer who have ceased to respond to standard therapy (known as refractory mCRC). However, ...

Jul 6, 2019

0

0

Targeted therapy combination improves survival in patients with advanced bowel cancer

New data have shown for the first time that a combination of targeted therapies can improve survival in patients with advanced bowel cancer. Results of the BEACON CRC Phase III trial have shown that triple therapy targeting ...

Jul 6, 2019

0

0

Triplet-targeted therapy improves survival for patients with advanced colorectal cancer and BRAF mutations

The three-drug combination of encorafenib, binimetinib and cetuximab significantly improved overall survival (OS) in patients with BRAF-mutated metastatic colorectal cancer (mCRC), according to results of the BEACON CRC Phase ...

Jul 6, 2019

0

2

Trump promises to reduce US drug prices to world's lowest

US President Donald Trump on Friday said his administration is working on an executive order to reduce US drug prices to match the lowest in the world.

Jul 6, 2019

1

0

Phys.org

Phys.org

Daily science news on research developments and the latest scientific innovations

Tech Xplore

Tech Xplore

The latest engineering, electronics and technology advances

ScienceX

Science X

The most comprehensive sci-tech news coverage on the web

Newsletters

Science X Daily and the Weekly Email Newsletter are free features that allow you to receive your favorite sci-tech news updates in your email inbox

Follow us

  • Top
  • Home
  • Search
  • Mobile version
  • Help
  • FAQ
  • About
  • Contact
  • Science X Account
  • Premium Account
  • Newsletter
  • Archive
  • Android app
  • iOS app
  • RSS feeds
  • Push notification
© Medical Xpress 2011 - 2025 powered by Science X Network
Privacy policy Terms of use Medical Disclaimer

E-mail newsletter

Follow us